<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870102</url>
  </required_header>
  <id_info>
    <org_study_id>DW330SR-1002(Ver1.1.)</org_study_id>
    <nct_id>NCT01870102</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open Label, Cross-over, Phase 1 Trial to Investigate the Pharmacokinetics in Multi-dose and the Food Effect in Single-dose of Pelubiprofen IR and Pelubiprofen SR in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Part 1 : A randomized, open Label, multiple doses, cross-over, phase I trial to investigate
      the pharmacokinetics of Pelubiprofen IR (Pelubiprofen 30mg) TID and Pelubiprofen SR
      (Pelubiprofen 45 mg) BID in healthy male volunteers Part 2 : A randomized, open label, single
      dose, cross-over, Phase I trial to investigate the food effect of Pelubiprofen SR
      (Pelubiprofen 45 mg) in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Part1) Cmax,ss of Pelubiprofen IR (Pelubiprofen 30mg)</measure>
    <time_frame>0(pre-dose), 0.25h, 0.5.h, 0.75h, 1h, 1.5h, 2h, 4h, 6h, 6.5h, 7h, 8h, 12h, 12.5h, 13h, 14h, 24h, 60h, 72h, 72.25h, 72.5h, 72.75h, 73h, 73.5h, 74h, 76h, 78h, 80h, 84h, 96h (total 30 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part1) Cmax,ss of Pelubiprofen SR (Pelubiprofen 45 mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 13h, 14h, 16h, 24h, 60h, 72h, 72.5h, 73h, 73.5h, 74h, 74,5h. 75h. 75.5h, 76h, 77h, 78h, 80h, 84h, 96h (total 32 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part1) Dose normalized AUCτ,ss of Pelubiprofen IR (Pelubiprofen 30mg)</measure>
    <time_frame>0(pre-dose), 0.25h, 0.5.h, 0.75h, 1h, 1.5h, 2h, 4h, 6h, 6.5h, 7h, 8h, 12h, 12.5h, 13h, 14h, 24h, 60h, 72h, 72.25h, 72.5h, 72.75h, 73h, 73.5h, 74h, 76h, 78h, 80h, 84h, 96h (total 30 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part1) Dose normalized AUCτ,ss of Pelubiprofen SR (Pelubiprofen 45 mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 13h, 14h, 16h, 24h, 60h, 72h, 72.5h, 73h, 73.5h, 74h, 74,5h. 75h. 75.5h, 76h, 77h, 78h, 80h, 84h, 96h (total 32 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part2) Cmax of Pelubiprofen IR (Pelubiprofen 30mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part2) Cmax of Pelubiprofen SR (Pelubiprofen 45 mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part2) AUClast of Pelubiprofen IR (Pelubiprofen 30mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part2) AUClast of Pelubiprofen SR (Pelubiprofen 45 mg)</measure>
    <time_frame>0(pre-dose), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h (15times each period, total 30 times)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>Pelubiprofen IR (Pelubiprofen 30 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg) fed condition</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen IR (Pelubiprofen 30mg) TID</intervention_name>
    <arm_group_label>Pelubiprofen IR (Pelubiprofen 30 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen SR (Pelubiprofen 45 mg) BID</intervention_name>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg)</arm_group_label>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition</arm_group_label>
    <arm_group_label>Pelubiprofen SR (Pelubiprofen 45 mg) fed condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy males aged 20~40 years

          -  BMI valued over 19 kg/m2, below 27 kg/m2

          -  Subjects whose blood pressure ; systolic BP over 90mmHg below 140mmHg, diastolic BP
             over 60mmHg below 90mmHg, stable station pulse over 45 bpm below 100 bpm

          -  Subjects who agree with double protective contraception or able to certificate already
             sterilization operation 1 day before administration of Investigational new drugs
             within 14 days after completion

          -  Subjects who voluntarily agreed with written consent

        Exclusion Criteria:

          -  Subjects with clinically significant disease or past medical history in hepatic,
             renal, GI tract, respiratory, musculoskeletal, endocrine, neuropsychiatry, blood tumor
             and cardiovascular system

          -  Subjects with GI tract disease (eg. Crohn's disease, peptic ulcer etc.) or surgery
             (except appendectomy and herniotomy) influence on administration Investigational new
             drugs

          -  Subjects with hypersensitivity reaction or clinically significant disease in drugs
             (Aspirin, NSAID anti-inflammatory agents and antibiotics) including Pelubiprofen and
             Food
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

